Sideways action for Sanofi — price forecast held back by long-term resistance

Traders Union
All News
Financial News
Sanofi slips 0.47% today to $86.02

Highlights

Sanofi (SAN) trades at $86.02, above MA-20 ($82.87) and MA-50 ($82.97), but faces long-term resistance at MA-200 ($91.19).
The FDA accepted Sanofi's Tzield supplemental biologics license application for expedited review, while EU regulators issued a negative opinion on Rezurock.
Technical signals are mixed with overbought oscillators and weak trend conviction, and SAN is forecast to trade between $84.28 and $84.63 with less than 20% upside probability.

[no content available for sentiment and flows]

The FDA has accepted Sanofi's supplemental biologics license application for Tzield, a stage 3 type 1 diabetes treatment, for expedited review under the National Priority Voucher pilot program, opening the door to potential fast-track approval in the US. Positive clinical data from Sanofi’s high-dose influenza vaccine study positions the company well in its key vaccine market. Meanwhile, FLC Capital Advisors' recent share acquisition and a negative opinion from EU regulators on Rezurock add mixed sentiment to the near-term outlook.

Mixed technical signals as buyers lead despite weak trend strength

For dynamic levels, the closest significant support is the Ichimoku Kijun at $81.60, with MA-50 ($82.97) as intermediate support and $87.00 as the next round-number resistance. Daily momentum signals are mixed — MACD remains positive but the ADX at 15.86 suggests weak trend conviction. Oscillators including RSI (75.41), Stoch RSI (66.15), and CCI (84.65) are in overbought or strong-bullish territory, and Bull/Bear Power indicates buyers are dominating intraday, though the Awesome Oscillator is negative and may warn of short-term weakness. The price is currently down 0.47% at $86.02, opening just below the previous close, and sits in a moderate volatility range for the day, reflecting a neutral-to-cautious intraday tone amidst diverging technical signals.

Downside bias expected as breakout odds remain minimal

Looking ahead to the next five trading days, expect SAN to fluctuate between $84.28 and $84.63. The probability of further price increases is very low (less than 20%), suggesting a downward move is more likely. The baseline scenario foresees SAN holding within a sideways corridor above $84.28, with upside only possible on a clear break above $87.00 — otherwise, a drop below $84.28 could trigger further declines, especially if market sentiment remains weak.

Viktoras Karapetjanc, analyst at Traders Union, sees Sanofi’s strong newsflow and short-term technical momentum counterbalanced by lingering longer-term resistance and mixed intraday signals. He believes the company’s scientific progress and regulatory tailwinds, particularly in the US, as well as growing institutional interest, support underlying sentiment — even as temporary overbought conditions and weak daily trend signals call for moderation. While the baseline scenario favors range-bound action, his outlook remains constructive provided the $84.28 support holds. "If broader sentiment stays stable and Sanofi preserves its fundamental momentum, a renewed rally above $87.00 is still on the table in the coming weeks."

Source of Data: SAN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.